Jasbg, did you even read my post? I realize English is not your first language, but I'm not sure how you arrived at your conclusion from what I posted. Read it again, very slowly this time.
I said..."Omega-3s broadly seem to have pharmacological potential similar to that of a drug, but a risk profile more akin to a nutrient." It's too bad that Amarin can't get this point across. "- referring to Vascepa!
My point was that I appreciated how she framed the benefit of Omega-3's (strong efficacy, very low risk), but wished that Amarin would take that same tack with Vascepa.
JR, I really dont know what to think of this post ? -----------------------------------------------------------------
Do you 'at all' - understand the Reduce-It trial - based on Vascepa - times 8 purified EPA ?
How can you seriously talk about general Omega 3 oil products in this context ? ------------------------------
You say you own 200k AMRN shares - representing an FDA approved medicine for greatly reducing risk for CDV patients !
I fail to understand how you can promote the endless number of ordinary OTC fish-oil products on the internet - being invested this BIG in AMRN and Vascepa ?